TORONTO (January 30, 2012) – Xagenic Inc., a start-up company created by Dr. Shana Kelley, in partnership with MaRS Innovation, today reached a significant milestone by successfully completing series A financing totaling $10 million.
Provincial Investment Supports Commercialization of Leading-Edge Molecular Diagnostic Screening Technology TORONTO (July 26, 2011) — Xagenic Inc., one of MaRS Innovation’s (MI) portfolio spin-off companies, was awarded $1 million in…
“York has become one of Canada’s fastest-growing centres for research and innovation,” said Stan Shapson, vice-president Research & Innovation at York University. “We typically get 10 to 20 discovery disclosures a year. Joining MaRS Innovation allows us to deliver the most competitive commercialization services to the researchers making these discoveries. We’re confident that membership in MaRS Innovation will boost that number and accelerate the commercialization of York’s most promising research.”
Earlier this year, York University launched its Innovation York office. Based in York Region, Innovation York works with other partner organizations in the Markham Convergence Centre to build upon research partnerships between York researchers and life science and technology companies based in York Region and the Greater Toronto Area. It’s also making York’s research and infrastructure more accessible to industry, government agencies and community partners.
MaRS Innovation provided crucial commercialization funding to support research from The Hospital for Sick Children MaRS Innovation (MI) and The Hospital for Sick Children (SickKids) have launched OtoSim Inc. to…
TORONTO (October 14, 2010) – Of the approximately 300 million people around the world who are diabetics, 45 million of them develop foot ulcers that bleed – and the infection from those ulcers can spread.
Working to halt this is Dr. Ping Lee, a professor at the University of Toronto’s (U of T) Leslie Dan Faculty of Pharmacy and GlaxoSmithKline chair in Pharmaceutics and Drug Delivery. He and his team have created a new sustained‐release form of nitric oxide (NO) that can not only stop the infections at wound sites, but also has the potential to speed up wound‐healing.
Still, the technology may have stayed on the shelf, even with three years worth of data demonstrating therapeutic relevance. The ultimate success of the technology is due to an effective collaboration between Dr. Lee, the Innovations and Partnerships Office (IPO) at U of T and MaRS Innovation (MI). Lee worked with IPO and MI to formulate a development plan in consultation with numerous industry advisors.
“We are excited about our partnership with the CDRD as it provides an opportunity for the two organizations to augment each other’s strengths, and leverage resources to generate attractive packages for potential partners, thereby supporting both of our organizations’ mandates of commercializing promising academic research. By entering into this innovative agreement, we believe the commercial potential of select projects in our pipeline will be enhanced,” said Dr. Raphael(Rafi) Hofstein, president and CEO of MI.
TORONTO (November 19, 2009) – In the drive to improve early detection and treatment of cancer, a pair of Toronto scientists has developed a unique technology that combines contrast agents with targeted, long-lasting nano-particles for use in multiple medical imaging platforms.
While contrast agents are routinely injected into patients to enhance the quality of medical images, different agents are currently required for various imaging modes (e.g. MRI, CT, PET) each with inherent strengths and limitations. By combining more than one contrast agent into a nano-particle for use in multiple types of imaging, not only are physicians and researchers able to use lower doses of contrast agents (with lower toxicity) but the nano-particle also enables targeted delivery to, and retention by, specific tumours.
TORONTO (June 30, 2009) – MaRS Innovation (MI) and the University of Toronto (U of T) are pleased to announce that they have entered into an agreement to collaboratively commercialize a novel sustained release formulation of nitric oxide (NO) for applications in wound healing, including diabetic ulcers.
“There are 300 million diabetics worldwide, of which some 15 per cent develop troublesome foot ulcers. This wound healing technology is extremely exciting, making it an early commercialization opportunity that MaRS Innovation has identified as being a potential win for some 45 million diabetics globally,” said Dr. Raphael (Rafi) Hofstein, president and CEO of MaRS Innovation.